Featured speaker and receiving honorary Doctor of Humane Letters at the University of New Haven Spring 2016 Commencement Ceremony
David Hallal is chief executive officer of Alexion, a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. He is also a member of the company’s board of directors.
In 2015, Hallal was named the company’s second CEO in its 24-year history, leading the company to expand its position as a global leader in rare diseases through an important acquisition and the approvals and launches of two highly innovative products.
Under Hallal’s leadership, the company returned to New Haven, where it was founded, establishing its new global headquarters that is a centerpiece of the Downtown Crossing redevelopment project.
Prior to becoming CEO, Hallal was chief operating officer and led strategic enterprise-wide initiatives that focused on diverse aspects of Alexion’s business, including the expansion of the company’s research and development pipeline and manufacturing operations. Previously, Hallal was Alexion’s first chief commercial officer.
Hallal joined Alexion in 2006 to build the company’s commercial operations, and he led the successful introduction of Soliris® (eculizumab), the company’s first product for the treatment of two ultra-rare, life-threatening, genetic blood disorders.
He played a principal role in leading many significant growth initiatives, including the development of Alexion’s 50-country operating platform. In addition to his leadership of all global commercial operations, Hallal has been responsible for country operations in each of Alexion’s affiliates in Europe/Middle East/Africa, Japan, Australasia and Latin America.
Hallal has more than 25 years of experience in the biopharmaceutical industry. Before joining Alexion, he advanced through positions of increasing responsibility in sales, marketing and management at Amgen, Biogen and OSI Eyetech, directing product launches in the areas of hematology, oncology, nephrology and immunology.
A member of the board of the Biotechnology Industry Organization, Hallal holds a bachelor’s degree in psychology from the University of New Hampshire.